Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Strategic Blueprint LLC

Strategic Blueprint LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,558 shares of the biopharmaceutical company’s stock after selling 572 shares during the quarter. Strategic Blueprint LLC’s holdings in Gilead Sciences were worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Manning & Napier Advisors LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,328,000. Legal & General Group Plc increased its position in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. GSA Capital Partners LLP acquired a new stake in Gilead Sciences in the 1st quarter valued at approximately $462,000. Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after acquiring an additional 33,162 shares during the period. Finally, Cetera Investment Advisers increased its position in Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after acquiring an additional 119,909 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.8 %

Shares of NASDAQ:GILD opened at $89.51 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $89.74. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $111.44 billion, a P/E ratio of 109.16, a price-to-earnings-growth ratio of 3.07 and a beta of 0.18. The firm has a fifty day moving average of $83.79 and a two-hundred day moving average of $74.12.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. On average, equities analysts expect that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on GILD shares. Piper Sandler restated an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a research report on Wednesday, September 11th. Barclays raised their target price on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $78.00 to $100.00 in a research report on Monday, October 7th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.